Related Experiment Video
Updated: May 21, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: A single practice experience
Achim Rothe1, Nathalie Bauer1, Lutz Dietze1
1Oncological Therapy Center MVZ West, Cologne, Germany.
Abstract:
Targeted treatment of non-small cell lung cancer (NSCLC) with driver aberrations has drastically improved the outcome of a subset of patients. However, for successful adaptation in the clinical routine, many stakeholders are involved, like comprehensive cancer centers, molecular pathology, peripheral hospitals, and oncology practices. Here, we present a single center experience in personalized treatment of lung cancer in Germany. Patients with advanced NSCLC and the need for systemic treatment after identification of a targetable driver mutation have been included in this analysis. Detection of the mutations was performed within a diagnostical network. Treatment was chosen depending on the respective driver mutation. We identified 58 patients (26 male, 32 female) with treatment relevant driver mutations: 33 patients (56.9 %) had an EGFR mutation, nine patients (15.5 %) presented with ALK translocation, five patients (8.6 %) were detected to have BRAF mutations, four had ROS1 translocations (6.9 %) and 8 patients had MET mutations (13.8 % each). In one patient, concomitant BRAF and MET amplifications were detected. 52 patients received targeted therapy. The median overall survival was 35.5 months (95 % CI, 18.0-52.9 months). 32 patients (64 %) received subsequent treatment after initiation of targeted therapy first-line. Our single-center experience demonstrates that advances in the field of targeted NSCLC therapy are quickly incorporated into clinical routine in Germany. Noteworthy, no new safety information was found.
Insights
Targeted therapy for non-small cell lung cancer (NSCLC) with driver mutations shows promising survival outcomes. This German single-center study confirms rapid clinical integration of these advanced NSCLC treatments.
Area of Science:
- Oncology
- Molecular Pathology
- Genetics
Background:
- Targeted therapies have improved outcomes for specific non-small cell lung cancer (NSCLC) patient subsets.
- Integrating personalized medicine into routine clinical practice involves multiple healthcare stakeholders.
Purpose of the Study:
- To present a single-center experience with personalized treatment of advanced NSCLC in Germany.
- To evaluate the clinical adaptation and outcomes of targeted therapies for NSCLC patients with driver mutations.
Main Methods:
- Analysis of advanced NSCLC patients requiring systemic treatment after identification of targetable driver mutations.
- Mutation detection performed within a diagnostic network, with treatment selection based on specific driver mutations.
- Retrospective review of patient data, including mutation types, targeted therapy administration, and survival outcomes.
Main Results:
- 58 patients with treatment-relevant driver mutations were identified: EGFR (56.9%), ALK (15.5%), BRAF (8.6%), ROS1 (6.9%), and MET (13.8%).
- 52 patients received targeted therapy, achieving a median overall survival of 35.5 months.
- 64% of patients received subsequent treatment after first-line targeted therapy, with no new safety concerns.
Conclusions:
- Advances in targeted NSCLC therapy are being rapidly incorporated into German clinical practice.
- Personalized treatment strategies for NSCLC demonstrate favorable survival outcomes and effective integration into routine care.
- The study highlights successful implementation of a molecular tumor board and diagnostic network for NSCLC treatment.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...